The Japan Alteplase Clinical Trial first demonstrated that AIS patients receiving r-tPA at a dose of 0.6 mg/kg could obtain comparable efficacy and safety to historical controls given 0.9 mg/kg r-tPA (4–8). This evidence concerns the gene PLAT and androgen insensitivity syndrome.